Calcilytix Therapeutics, Inc. Report issue

For profit Phase 2
Founded: San Francisco CA United States (2018)

Organization Overview

First Clinical Trial
2020
NCT04581629
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Calcilytix Therapeutics, Inc. | Calcilytix Therapeutics, Inc., a BridgeBio company